Yes, definitely assuming no limiting irAEs. There is clear activity to IO monotherapy in mRCC as evidenced by KEYNOTE 427 and other datasets. Combination therapy is superior, however, so dose interruption/modification of the TKI should be attempted before discontinuing permanently.